A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery

Evan Rosenbaum, Rashmi Chugh, Christopher W. Ryan, Mark Agulnik, Mohammed M. Milhem, Suzanne George, Robin L. Jones, Bartosz Chmielowski, Brian A. Van Tine, Hussein Tawbi, Anthony D. Elias, William L. Read, G. Thomas Budd, Li Xuan Qin, Eve T. Rodler, Joe Hirman, Paul Weiden, Cathryn M. Bennett, Philip O. Livingston, Govind RagupathiDavid Hansen, Sandra P. D'Angelo, William D. Tap, Gary K. Schwartz, Robert G. Maki, Richard D. Carvajal

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery'. Together they form a unique fingerprint.

Medicine & Life Sciences